Literature DB >> 28292469

Down-regulation of the placental BCRP/ABCG2 transporter in response to hypoxia signaling.

Lissa N Francois1, Ludwik Gorczyca2, Jianyao Du3, Kristin M Bircsak2, Elizabeth Yen4, Xia Wen2, Mei-Juan Tu5, Ai-Ming Yu5, Nicholas P Illsley6, Stacy Zamudio6, Lauren M Aleksunes7.   

Abstract

INTRODUCTION: The BCRP/ABCG2 efflux transporter protects the developing fetus by limiting the transplacental transfer of drugs and chemicals and prevents the apoptosis of trophoblasts. The purpose of this study was to determine whether hypoxia-related signaling alters placental BCRP expression and function in vitro and in human pregnancies.
METHODS: Human BeWo choriocarcinoma cells were treated with the hypoxia mimetic, cobalt chloride (CoCl2), or 3% oxygen for 24-48 h. Activation of HIF-1α signaling and regulation of BCRP was assessed using qPCR, ELISA, western blotting and a fluorescent substrate transport assay. In addition, healthy term placentas from high altitude pregnancies with chronic hypoxia were assessed for BCRP expression.
RESULTS: CoCl2 and 3% oxygen increased HIF-1α protein signaling and decreased the mRNA and protein expression of BCRP by 30-75% in BeWo cells. Reduced BCRP expression corresponded with impaired efflux activity during hypoxia as evidenced by accumulation of the substrate Hoechst 33342. A number of transcription factors known to regulate BCRP, including AHR, NRF2 and PPARγ, were also coordinately down-regulated by 3% oxygen in BeWo cells. Moreover, women who gave birth at a high altitude (3100 m) exhibited signs of chronic placental hypoxia, including enhanced protein expression of the HIF-1α target GLUT1, and had reduced BCRP levels in microvillous membranes compared to women at a moderate altitude (1600 m). DISCUSSION: This study provides novel insight into the regulation of the placental BCRP transporter by hypoxia, which may be important for exposure of the fetus to chemicals during early development and in hypoxia-related pregnancy disorders.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  ABCG2; BCRP; Hypoxia; Placenta; Transporter

Mesh:

Substances:

Year:  2017        PMID: 28292469      PMCID: PMC5354084          DOI: 10.1016/j.placenta.2017.01.125

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  43 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  P-glycoprotein and breast cancer resistance protein expression in human placentae of various gestational ages.

Authors:  Anita A Mathias; Jane Hitti; Jashvant D Unadkat
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2005-06-16       Impact factor: 3.619

3.  Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues.

Authors:  M Maliepaard; G L Scheffer; I F Faneyte; M A van Gastelen; A C Pijnenborg; A H Schinkel; M J van De Vijver; R J Scheper; J H Schellens
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

4.  Expression of hypoxia-inducible factor-1 by trophectoderm cells in response to hypoxia and epidermal growth factor.

Authors:  Wooyoung Jeong; Fuller W Bazer; Gwonhwa Song; Jinyoung Kim
Journal:  Biochem Biophys Res Commun       Date:  2015-11-24       Impact factor: 3.575

5.  Aryl hydrocarbon receptor is a transcriptional activator of the human breast cancer resistance protein (BCRP/ABCG2).

Authors:  Kah Poh Tan; Bernice Wang; Mingdong Yang; Paul C Boutros; Jane Macaulay; Haibo Xu; Andrew I Chuang; Kazuhiro Kosuge; Mika Yamamoto; Shinichiro Takahashi; Alex M L Wu; Douglas D Ross; Patricia A Harper; Shinya Ito
Journal:  Mol Pharmacol       Date:  2010-05-11       Impact factor: 4.436

6.  Dynamic HIF1A regulation during human placental development.

Authors:  Francesca Ietta; Yuanhong Wu; Jennifer Winter; Jing Xu; Jinxia Wang; Martin Post; Isabella Caniggia
Journal:  Biol Reprod       Date:  2006-04-12       Impact factor: 4.285

7.  Cobaltous chloride and hypoxia inhibit aryl hydrocarbon receptor-mediated responses in breast cancer cells.

Authors:  Shaheen Khan; Shengxi Liu; Matthew Stoner; Stephen Safe
Journal:  Toxicol Appl Pharmacol       Date:  2007-05-25       Impact factor: 4.219

8.  The ABC transporter BCRP/ABCG2 is a placental survival factor, and its expression is reduced in idiopathic human fetal growth restriction.

Authors:  Denis A Evseenko; Padma Murthi; James W Paxton; Glen Reid; B Starling Emerald; K M Mohankumar; Peter E Lobie; Shaun P Brennecke; Bill Kalionis; J A Keelan
Journal:  FASEB J       Date:  2007-06-26       Impact factor: 5.191

9.  A human placenta-specific ATP-binding cassette gene (ABCP) on chromosome 4q22 that is involved in multidrug resistance.

Authors:  R Allikmets; L M Schriml; A Hutchinson; V Romano-Spica; M Dean
Journal:  Cancer Res       Date:  1998-12-01       Impact factor: 12.701

10.  Effect of breast cancer resistance protein (Bcrp/Abcg2) on the disposition of phytoestrogens.

Authors:  Junichi Enokizono; Hiroyuki Kusuhara; Yuichi Sugiyama
Journal:  Mol Pharmacol       Date:  2007-07-20       Impact factor: 4.436

View more
  13 in total

1.  Role of the efflux transporters BCRP and MRP1 in human placental bio-disposition of pravastatin.

Authors:  Marjan Afrouzian; Rabab Al-Lahham; Svetlana Patrikeeva; Meixiang Xu; Valentina Fokina; Wayne G Fischer; Sherif Z Abdel-Rahman; Maged Costantine; Mahmoud S Ahmed; Tatiana Nanovskaya
Journal:  Biochem Pharmacol       Date:  2018-09-12       Impact factor: 5.858

Review 2.  An update on expression and function of P-gp/ABCB1 and BCRP/ABCG2 in the placenta and fetus.

Authors:  Lyrialle W Han; Chunying Gao; Qingcheng Mao
Journal:  Expert Opin Drug Metab Toxicol       Date:  2018-08-03       Impact factor: 4.481

3.  Establishment of an in vitro placental barrier model cultured under physiologically relevant oxygen levels.

Authors:  Michael K Wong; Edward W Li; Mohamed Adam; Ponnambalam R Selvaganapathy; Sandeep Raha
Journal:  Mol Hum Reprod       Date:  2020-05-15       Impact factor: 4.025

Review 4.  Fetomaternal Expression of Glucose Transporters (GLUTs)-Biochemical, Cellular and Clinical Aspects.

Authors:  Rafal Sibiak; Katarzyna Ozegowska; Ewa Wender-Ozegowska; Pawel Gutaj; Paul Mozdziak; Bartosz Kempisty
Journal:  Nutrients       Date:  2022-05-12       Impact factor: 6.706

Review 5.  Regulation of Placental Efflux Transporters during Pregnancy Complications.

Authors:  Danielle Kozlosky; Emily Barrett; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2022-01-06       Impact factor: 3.579

6.  Epigenetic Regulation of Multidrug Resistance Protein 1 and Breast Cancer Resistance Protein Transporters by Histone Deacetylase Inhibition.

Authors:  Dahea You; Jason R Richardson; Lauren M Aleksunes
Journal:  Drug Metab Dispos       Date:  2020-03-19       Impact factor: 3.922

7.  Bioengineered NRF2-siRNA Is Effective to Interfere with NRF2 Pathways and Improve Chemosensitivity of Human Cancer Cells.

Authors:  Peng-Cheng Li; Mei-Juan Tu; Pui Yan Ho; Joseph L Jilek; Zhijian Duan; Qian-Yu Zhang; Ai-Xi Yu; Ai-Ming Yu
Journal:  Drug Metab Dispos       Date:  2017-10-23       Impact factor: 3.922

8.  Role of Elevated SFLT-1 on the Regulation of Placental Transporters in Women With Pre-Eclampsia.

Authors:  Dea Kojovic; Natalie V Workewych; Micheline Piquette-Miller
Journal:  Clin Transl Sci       Date:  2020-02-03       Impact factor: 4.689

9.  Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition via the regulation of target ADME gene expression.

Authors:  Xin Li; Ye Tian; Mei-Juan Tu; Pui Yan Ho; Neelu Batra; Ai-Ming Yu
Journal:  Acta Pharm Sin B       Date:  2018-12-11       Impact factor: 11.413

10.  Low oxygen tension differentially regulates the expression of placental solute carriers and ABC transporters.

Authors:  Ludwik Gorczyca; Jianyao Du; Kristin M Bircsak; Xia Wen; Anna M Vetrano; Lauren M Aleksunes
Journal:  FEBS Lett       Date:  2020-10-07       Impact factor: 4.124

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.